It would be easier to pretend cryonics is a finished product. It is not, and saying so plainly is more honest and more interesting. Cryonics is a research program that happens to have members, and the quality of the preservation you would receive today is the cumulative output of decades of incremental work that is still very much underway. The right question is not whether the technology is done. It is whether the trend lines are moving the right way, and what work is moving them.
This article is the concrete answer: the specific R&D that Tomorrow.bio and its partners pursue, and why each line of work translates into better odds for the structure that matters. Almost all of it reduces to the same two levers we obsess over elsewhere, getting protectant in faster and more evenly, and storing the result more stably.
Better protectant, less toxicity
The cryoprotectant solution is simultaneously the hero and the problem. It is what lets tissue vitrify into a glass instead of forming destructive ice, and it is also mildly toxic, which means every formulation is a negotiation between protection and harm.
So a central R&D thread is optimizing perfusion protocols and cryoprotectant formulations to lower toxicity while keeping reliable vitrification. This is the modern continuation of a long lineage, the same line of work that produced today's human-use agents through generation after generation of vitrification procedures, each one fixing a specific flaw in the last. Lower toxicity means less damage to the very structure being preserved, which is the cleanest possible quality improvement.
Handling the cases that are not ideal
In a textbook case the team is standing by, legal death is clean, and perfusion begins within minutes. Reality is less tidy. Some members die far from a team, some after prolonged ischemia, some in circumstances that delay everything.
A serious research program cannot only optimize the best case; it has to improve outcomes across the messy distribution of real ones. That means studying how different degrees of ischemic damage affect tissue, and developing protocols that get the best achievable result even when the early window was less than ideal. This is unglamorous, important work, and it is closely tied to the race against cellular decay that defines the hard cases in the first place.
Storage that fractures less
Getting a patient vitrified is not the end of the engineering. Cooling all the way to -196°C introduces thermal stress that can cause fracturing, a real and acknowledged form of damage. One active line of development is Intermediate Temperature Storage, holding patients nearer -140°C in the storage dewars to sit safely below the glass transition while reducing the stress that drives fractures.
The trade-off is honest and worth stating: storing warmer than liquid nitrogen reduces fracturing risk but narrows the safety margin against any temperature excursion, so the engineering has to be correspondingly tighter. R&D here is the work of finding and holding that better operating point.
Measuring quality instead of guessing at it
For much of the field's history, preservation quality was described in adjectives. A maturing field replaces adjectives with metrics, and a meaningful share of current R&D is exactly that move toward measurement.
The clearest example is developing and applying quality metrics like S-MIX, a standardized measure of ischemic exposure, so that cases can be compared and protocols judged by evidence rather than anecdote. Feeding those metrics back into the per-case quality-check procedures turns every preservation into a data point that can improve the next one. You cannot optimize what you do not measure, and a lot of R&D is simply building the ability to measure.
People and the wider research ecosystem
Some of the highest-leverage research is not chemistry at all, it is logistics and training. Equipping and training local teams to shorten response times directly attacks ischemia at its source, and an extra team in the right city can improve more outcomes than a marginal tweak to a solution.
Beyond Tomorrow.bio itself, the work sits inside a broader ecosystem. The non-profit European Biostasis Foundation pursues applied and translational research alongside running the storage facility, and collaborators in the field, such as groups like Advanced Neural Biosciences working on ice-free brain preservation approaches, push the basic science forward. There is genuine published groundwork underneath all of this, from organ vitrification to memory retention after vitrification in simple organisms, and we keep a running list in relevant research papers. None of these efforts promises revival on a schedule; together they make the preserved structure more faithful and the long wait more secure.
Cryonics is a research program with members, and its honest promise is not perfection today but a steadily rising floor of quality, won one protocol, one metric, and one shorter response time at a time.
That is the case for optimism that does not require faith. Each open problem here is the kind that yields to engineering rather than miracles, and the broad project of advancing the field is the slow, accountable work of grinding those problems down, including the deeper challenges of reversible cryopreservation that sit further along the same road.